Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure

The Impairment of Social and Environmental Relationships in Patients With Heart Failure Correlated With Therapeutic Class

Background and objectives Heart failure (HF) significantly influences the quality of life, both physically and emotionally, as well as social and environmental relationships. One major objective of HF treatment is to maintain or improve the quality of life. The aims of the study were to assess the impact of HF on social relationships and the relationship with the environment, according to therapeutic class and the presence of comorbidities, and to identify predictive factors for the impairment of these dimensions of the quality of life. Materials and methods This study was based on a cross-sectional survey; 252 patients with HF who have referred themselves to the medical rehabilitation department of the "Avram Iancu" Clinical Hospital, Oradea, between February 2023 and February 2024 were included. The patients were divided into two groups (Group HF-S/V, patients undergoing treatment with sacubitril/valsartan; Group HF-CT, patients receiving conventional therapy). All patients were asked to complete two assessment tools: the Charlson Comorbidity Index (CCI) questionnaire and the World Health Organization Quality of Life Brief Version (WHOQOL-BREF) questionnaire. Results The mean values obtained per the domain of social relationships were significantly better for Group HF-CT (65.762 ± 12.519 versus 61.266 ± 12.428, p = 0.024). The mean values obtained on the domain of social relations and in relation to the environment were significantly better for Group HF-CT (65.762 ± 12.519 versus 61.266 ± 12.428, p = 0.024; 61.333 ± 13.461 versus 51.719 ± 16.769, p < 0.001). Both dimensions of the quality of life correlate with age and CCI (F = 7.793, p < 0.001, for social relationships; F = 16.821, p < 0.001, for relationship with the environment). Conclusions Social relationships and the relationship with the environment are affected in HF patients and correlate with age and comorbidity index, regardless of the type of therapy.

Use of sacubitril/valsartan in patients with heart failure: evidence from the real world

BACKGROUND

To characterize the use of sacubitril/valsartan in a group of patients with heart failure in Colombia.

RESEARCH DESIGN AND METHODS

Follow-up study of patients with heart failure who started sacubitril/valsartan and were affiliated with the Colombian health system between 2019 and 2021. Sociodemographic, clinical, and pharmacological variables and adherence and persistence of use were identified.

RESULTS

A total of 514 patients were identified, with a mean age of 65.7 years, 73.7% of whom started sacubitril/valsartan at low doses, and only 12.5% reached the maximum dose. Adherence was 78.2% and persistence was 56.8% at 1 year of follow-up. The increase in systolic blood pressure (odds ratio (OR): 1.01; 95% CI: 1.00-1.03) and the use of β-blockers (OR: 2.63; 95% CI: 1.42-4.85) were correlated with a greater persistence, while receiving furosemide (OR: 0.59; 95% CI: 0.39-0.89) and not having received renin - angiotensin - aldosterone system inhibitors in the 3 months before starting sacubitril/valsartan (OR: 0.48; 95% CI: 0.31-0.76) were associated with lower persistence.

CONCLUSIONS

The persistence of treatment 1 year after starting sacubitril/valsartan was not high, and a small proportion of patients reached the target dose of the drug. Nontitration of the drug dose was common.

The Rare Condition of Left Ventricular Non-Compaction and Reverse Remodeling

Left ventricular non-compaction (LVNC) is a rare disease defined by morphological criteria, consisting of a two-layered ventricular wall, a thin compacted epicardial layer, and a thick hyper-trabeculated myocardium layer with deep recesses. Controversies still exist regarding whether it is a distinct cardiomyopathy (CM) or a morphological trait of different conditions. This review analyzes data from the literature regarding diagnosis, treatment, and prognosis in LVNC and the current knowledge regarding reverse remodeling in this form of CM. Furthermore, for clear exemplification, we report a case of a 41-year-old male who presented symptoms of heart failure (HF). LVNC CM was suspected at the time of transthoracic echocardiography and was subsequently confirmed upon cardiac magnetic resonance imaging. A favorable remodeling and clinical outcome were registered after including an angiotensin receptor neprilysin inhibitor in the HF treatment. LVNC remains a heterogenous CM, and although a favorable outcome is not commonly encountered, some patients respond well to therapy.

Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease

The purpose of this Special Issue is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidaemia, and cardiovascular disease [...].